dabigatran has been researched along with Arterial Occlusive Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohebbi, N | 1 |
| Amara, W; Guedeney, P; Iusuf, A | 1 |
| Arnold, DM; Bhakta, V; Crowther, MA; Eltringham-Smith, LJ; Lambourne, MD; Sheffield, WP | 1 |
| Alla, F; Billionnet, C; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG | 1 |
| Hess, C | 1 |
| Dahl, OE | 1 |
| Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C | 1 |
2 review(s) available for dabigatran and Arterial Occlusive Diseases
| Article | Year |
|---|---|
[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Topics: Anticoagulants; Arterial Occlusive Diseases; Atrial Fibrillation; Comorbidity; Contraindications; Coronary Disease; Dabigatran; Glomerular Filtration Rate; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2018 |
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.
Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Humans; Risk Factors; Thromboembolism; Treatment Outcome; Venous Thromboembolism | 2012 |
6 other study(ies) available for dabigatran and Arterial Occlusive Diseases
| Article | Year |
|---|---|
[Ischemic stroke after cardioversion and atrial flutter ablation in a patient taking dabigatran].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Cerebral Arteries; Dabigatran; Echocardiography; Electric Countershock; Humans; Male; Stroke | 2013 |
γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
Topics: Animals; Anticoagulants; Arterial Occlusive Diseases; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coagulation; Carotid Arteries; Catalytic Domain; Cell Line; Cricetinae; Dabigatran; Humans; Mice; Mutation; Recombinant Proteins; Thrombin; Thrombin Time | 2014 |
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Middle Aged; Risk; Rivaroxaban; Thromboembolism; Thrombophilia; Vitamin K; Warfarin; Young Adult | 2015 |
[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Blood Coagulation; Dabigatran; Enoxaparin; Female; Humans; Lower Extremity; Male; Middle Aged; Osteoarthritis, Hip; Perioperative Care; Postoperative Complications; Retrospective Studies; Risk Adjustment; Russia; Thrombosis | 2016 |
[Always more amputations in Germany?].
Topics: Aged; Amputation, Surgical; Anticoagulants; Arterial Occlusive Diseases; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Germany; Humans; Morpholines; Peripheral Vascular Diseases; Pyridines; Rivaroxaban; Thiophenes; Thrombosis | 2008 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Embolectomy; Embolism; Enoxaparin; Fatal Outcome; Femoral Artery; Humans; International Normalized Ratio; Male; Phenprocoumon; Vertebrobasilar Insufficiency | 2012 |